Letter to the Editor
Pneumocystis carinii jiroveci Pneumonia Following Infliximab Infusion for Crohn Disease: Emphasis on Prophylaxis
To the Editor:
Pneumocystis carinii pneumonia (PCP) is known to be associated with immunodeficiency states such as AIDS, malignancies and chemotherapy. Lately the occurrence of PCP has increased as the indications for use of immunosuppressive/immunomodulator therapies have broadened.1,2 PCP following infliximab therapy for Crohn disease, although still uncommon, is increasing in occurrence. Although recommendations for prophylaxis for PCP are well known in HIV patients, there are no guidelines for prophylaxis in non-HIV patients. There has been mention of considering prophylaxis in patients who are receiving immunosuppressive medications or who have an underlying acquired or inherited immunodeficiency.3 In this letter, we describe a case of PCP following the second dose of infliximab infusion in a woman with Crohn disease.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view your purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.